Drug Therapy in Neonates and Pediatric Patients

Principles of Clinical Pharmacology

Volumn , Issue , 2007, Pages 359-373

  Fox, Elizabeth ^a   Balis, Frank M ^a  

^a Pediatric Oncology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872377801     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369417-1/50063-8     Document Type: Chapter

References (55)

1. Lietman PS. Chloramphenicol and the neonate-1979 view. Clin Perinatol 1979, 6:849-853.
2. Burns LE, Hodgman JE, Cass AB. Fatal circulatory col-lapse in premature infants receiving chloramphenicol. N Engl J Med 1959, 261:417-423.
3. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. N Engl J Med 1960, 262:5337-5339.
4. Klecker RW, Collins JM, Yarchoan R, Thomas R, Jenkins JF, Broder S, Myers CE. Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymide: A novel pyrimidine analog with poten-tial application for the treatment of pa. Clin Pharmacol Ther 1987, 41:R1495-R1503.
5. Balis F, Pizzo P, Eddy J, Wilfert C, McKinney R, Scott G, Murphy RF, Jaronsinski PF, Falloon J, Poplack DG. Pharmacokinetics of zidovudine admin-istered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989, 114:457-463.
6. Mirochnick M, Capparelli E, Dankner W, Sperling RS, vanDyke R, Spector SA. Zidovudine pharmacokinet-ics in premature infants exposed to human immun-odeficiency virus. Antimicrob Agents Chemother 1998, 42:1926-1929.
7. Boucher FD, Modlin JF, Weller S, Ruff AA, Mirochnick M, Pelton SP, Wilfert C, McKinney R, Crain MJ, Elkins MM, Blum MR, Prober CG. Phase 1 evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993, 122:545-553.
8. O'Sullivan MJ, Boyer PJ, Scott GB, Parks PW, Weller S, Blum R, Balsley J, Bryson YJ. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immun-odeficiency virus and their infants: Pha. Am J Obstet Gynecol 1993, 168:1137-1143.
9. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, vanDyke R, Bey M, Shearer W, Jacobson RL, Jimenez E, O'Neill E, Bazin B, Delfraissy J-F, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J. Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment. N Engl J Med 1994, 331:1277-1287.
10. Loebstein R, Koren G. Clinical pharmacology and ther-apeutic drug monitoring in neonates and children. Pediatr Rev 1998, 19:423-428.
11. Friedman M, Shalala DE. Regulations requiring man-ufacturers to assess the safety and effectiveness of new drugs and biological products in peditric patients (21 CRF Parts 201,312,. Federal Register 1998, 63:66632-66672.
12. Cooper KJ. Pediatric marketing exclusivity -as altered by the Best Pharmaceuticals for Children Act of 2002. Food Drug Law J 2002, 57:519-544.
13. Steinbrook R. Testing medications in children. N Engl J Med 2002, 347:1462-1470.
14. McKinney RE Congress the FDA and the fair development of new medications for children. Pedi-atrics 2003, 112:669-670.
15. Hirschfeld S. Pediatric Patients and Drug Safety. J Pediatr Hematol Oncol 2005, 27:122-124.
16. Leeder JS, Adciock K, Gaedigk A, Gotschall R, Wilson JT, Kearns GL. Delayed maturation of cytochrome P450 3A (CYP3A) activity in vivo in the first year of life [abstract]. Pediatr Res 2000, 47:472A.
17. Hubbard W. International conference on harmonisa-tion; E11: Clinical investigation of medicinal prod-ucts in the pediatric population. Federal Register 2000, 65:139-148.
18. Kearns G, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental phar-macology -Drug disposition action and therapy in infants and children. N Engl J Med 2003, 349:889-893.
19. Routledge P. Pharmacokinetics in children. J Antimi-crob Chemother 1994, 34(suppl A):758-761.
20. Reed MD, Besunder JB. Developmental pharmacol-ogy: Ontogenic basis of drug disposition. Pediatr Clin North America 1989, 36:380-387.
21. Linday L, Dobkin JF, Wang TC, Butler VP, Saha, Lindenbaum R. Digoxin inactivation by the gut flora in infancy and childhood. Pediatrics 1987, 79:197-204.
22. Kurtz H, Michels H, Stickel HH. Differences in the binding of drugs to plasma proteins from newborns and adult man. Eur J Clin Pharmacol 1977, 11:262-267.
23. Morselli PL. Clinical pharmacology of the perina-tal period and early infancy. Clin Pharmacokinet 1989, 17(suppl 1):47-74.
24. Kaufman RE Pediatric pharmacology. Pediatric pharmacology, therapeutic principles in practice 1992, 1567-1572. WB Saunders, Philadelphia. J.V. Aranda, S.J. Yaffe (Eds.).
25. Kearns GL, Reed MD. Clinical pharmacokinetics in infancy and children, a reappraisal. Clin Pharma-cokinet 1989, 17(suppl 1):281-298.
26. Aranda J, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlou H, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in premature newborn infant. Acta Paediatr 1997, 86:551-561.
27. Pikkarainen PH, Raiha NC. Development of aldohol dehydrogenase activity in human liver. Pediatr Res 1967, 1:582-585.
28. de Wildt S, Kearns GL, Leeder S, van den Anker JN. Glucuronidation in humans. Clin Pharmacokinet 1999, 36:501-505.
29. Miller RP, Roberts, Fischer LJ. Acetaminophen elim-ination kinetics in neonates children and adults. Clin Pharmacol Ther 1976, 19:404-408.
30. Kearns GL. Pharmacogenetics and development: Are infants and children at increased risk for adverse outcomes?. Curr Opin Pediatr 1995, 7:324-328.
31. Blake MJ, Castro L, Leeder JS, Kearns GL. Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005, 1 0:1132-1137.
32. de Wildt S, Kearns GL, Leeder S, van den Anker JN. Cytochrome P450 3A ontogeny and drug distribution. Clin Pharmacokinet 1999, 37:94-95.
33. Cresteil T. Onset of xenobiotic metabolism in chil-dren: Toxicological implications. Food Addit Contam 1998, 15:812-813.
34. Oesterheld A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998, 8:497-499.
35. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver -evidence that the shift between CTP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 1997, 247:1124.
36. Treluyer J-M, Rey E, Sonnier M, Pons G, Cresteil T. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001, 52:42-47.
37. Kearns GL, Robinson PK, Wilson JT, Wilson-Costelo D, Knight GR, Ward RM, van den Anker JN Pedatric Pharmacology Research Unit Network. Cisapride dis-position in neonates and infants: In vivo reflection of cytochrome P450 3A4 ontogeny. Clin Pharmacol Ther 2003, 74:1253-1255.
38. Treluyer J, Jacqz-Aigrain E, Alvarez F, Cresteil T. Expression of CYP2D6 in developing human liver. Eur J Biochem 1991, 202:453-457.
39. Pons G, d'Athis P, Rey E, deLauture D, Richard MO, Badoul J, Olive G. Gentamicin monitoring in neonates. Ther Drug Monit 1988, 10:459-462.
40. Aperia A, Broberger O, Thodenius K, Zetterstrom R. Development of renal control of salt and fluid home-ostasis during the first year of life. Acta Pediatr Scand 1975, 64:431-433.
41. Guignard J, Torrado A, Da Cunha O, Gautier E. Glomerular filtration in the first three weeks of life. J Pediatr 1975, 87:367-370.
42. Kraus DM, Fischer JH, Reitz SJ, Kecskes SA, Yeh TF, McCulloch KM, Tung EC CwikMJ. Alterations in theophylline metabolism during the first year of life. Clin Pharmacol Ther 1993, 54:1234-1236.
43. Grygiel JJ, Birkett DJ, Phill D. Effect of age on pat-terns of theophylline metabolism. Clin Pharmacol Ther 1980, 28:151-162.
44. Ueno K, Kasuhiko T, Shokawa M, Horiuchi Y. Age-dependent changes of renal clearance of theophylline in asthmatic children [letter]. Ann Pharmacother 1994, 28:1318-1321.
45. Tserng K-Y, Takieddine FN, King KC. Developmen-tal aspects of theophylline metabolism in premature infants. Clin Pharmacol Ther 1983, 33:787-794.
46. Milavetz G, Vaughan LM, Weinberger MM, Hendeles L. Evaluation of a scheme for estab-lishing and maintaining dosage of theophylline in ambulatory patients with chronic asthma. J Pediatr 1986, 109:351-354.
47. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997, 57:407-412.
48. Slattery JT, Sanders JE, Buckner RL, Schaffer RL, Lambert KW, Langer FP, Anasetti C, Bensinger WI, Fisher LD, Appelbaum FR, Hansen JA. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995, 16:880-884.
49. Bleyer WA. Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 1977, 61:808-812.
50. Bleyer WA, Coccia PF, Sather HN, Level C, Lukens J, Niebrugge DJ, et al. Reduction in central nervous sys-tem leukemia with a pharmacokinetically dervived intrathecal methotrexate dosage regimen. J Clin Oncol 1983, 1:137-144.
51. Crom WR, deGraaf SS, Synold T, Uges DR, Bloemhoef H, Rivera G, Christensen M, Mahmoud H, Evans WE. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994, 125:1510-1516.
52. Seri I, Abbasi S, Wood DC, Gerdes JS. Regional hemo-dynamic effects of dopamine in the sick preterm neonate. J Pediatr 1998, 133:1173-1180.
53. Rey E, Treluyer T-M, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998, 35:423-428.
54. American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995, 95:66632-66672.
55. Cohen S. The Pediatric Pharmacology Research Unit (PPRU) Network and its role in meeting pediatric labeling needs. Pediatrics 1999, 105:519-544.